⁃ Subprotocol A, B, and C

• Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).

• Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before AMG 193 dosing.

• Homozygous MTAP-deletion

• Able to swallow and retain PO administered study treatment.

• Disease measurable as defined by RECIST v1.1.

⁃ Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.

⁃ Arm A (AMG 193 + carboplatin + paclitaxel + pembrolizumab):

⁃ \- Predominantly squamous histology.

⁃ Arm B (AMG 193 + carboplatin + pemetrexed + pembrolizumab):

⁃ \- Predominantly non-squamous histology.

⁃ Arm C (AMG 193 + pembrolizumab):

⁃ \- PD-L1 positive.

⁃ Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.

⁃ Subprotocol C

• Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.

• Brain lesion meeting RANO-BM criteria for measurable disease.